


DUTHY GETNE T1812

PI: Dr. Jaume Capdevila

A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma (DUTHY study)

STUDY DESIGN





DUTHY GETNE T1812 PI: Dr. Jaume Capdevila

A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma (DUTHY study)

STUDY DESIGN

- Cohort 1 and 2 patients will be included according to a two-stage Simon design, with the inclusion of 17 patients in phase I and 19 patients in phase II, for a total of 36 patients / cohort.
 - If ≥ 5 patients of the 17 patients included in the first phase do not progress or have unacceptable toxicity at 6 months, the second phase will begin, including 19 more patients.
- Cohort 3 patients will be included in a single phase, up to a total of 12 patients.

